|Articles|March 3, 2021

T Cells Crucial in Avoiding Symptoms of COVID-19

Author(s)Killian Meara

Cells reactive to SARS-CoV-2 peptide pools were found in all anti-NP IgG–positive individuals.

Recent data published in the Journal of Experimental Medicine has suggested that T cells are a key component in clearing the COVID-19 virus without developing any symptoms. An efficient response can produce a careful balance of pro and anti-inflammatory molecules. The study was conducted by the Saw Swee Hock School of Public Health in Singapore, in collaboration with the National University of Singapore and the National Research Foundation of Singapore.

An infection with SARS-CoV-2 triggers an immune response by antibodies and T cells that recognize the virus and attempt to clear it from the body. However, this response sometimes causes an excessive amount of inflammation that can damage tissue and worsen symptoms.

It is still unknown what determines someone who is infected from showing symptoms, though some studies have suggested those who are symptomatic produce fewer anti-SARS-CoV-2 antibodies than those with symptoms.

"Asymptomatic individuals constitute a variable but often large proportion of infected individuals, and they should hold the key to understanding the immune response capable of controlling the virus without triggering pathological processes," Antonio Bertoletti, a professor at the Duke-NUS Medical School in Singapore said.

Investigators behind the study analyzed a group of migrant workers who were exposed to COVID-19 over the course of 6 weeks/ They took blood samples from 85 who became infected and were asymptomatic and compared them to 75 who were hospitalized with a mild to moderate case of the disease.

Findings showed that shortly after the infection, the frequency with which the T cells recognized the virus was similar in both groups. However, the T cells of the asymptomatic group produced a greater amount of two types of proteins called IFN-γ and IL-2. The 2 proteins help coordinate the response of the immune system when there is a virus or pathogen present. Additionally, the asymptomatic group showed a balanced, well-proportioned mix of pro and anti-inflammatory molecules, while the other group had a disproportionate amount of proinflammatory molecules.

"Overall, our study suggests that asymptomatic SARS-CoV-2-infected individuals are not characterized by a weak antiviral immunity; on the contrary, they mount a highly efficient and balanced anti-viral cellular response that protects the host without causing any apparent pathology," the investigators said.


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.